© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
January 23, 2020
Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.
December 06, 2019
Biosimilar to Remicade
November 18, 2019
Expected U.S. launch in 2023.
October 01, 2019
Biosimilars may need more time to devleop in the market.
September 27, 2019
Biologic medicines could lower spending by $153 billion by 2023.
September 11, 2019
New changes are making it more difficult for generics and biosimilars to compete on formularies.
July 23, 2019
CD20-directed antibody indicated for several cancers and other conditions.
May 10, 2019
Biosimilar guidance provides “clarity” for drug developers.
March 12, 2019
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.
March 08, 2019
Only new biosimilars and interchangeables will recieve four-letter suffixes.